TMO - Agilent seen as a beneficiary in post-pandemic recovery trade at Citi

Agilent Technologies ([[A]] +0.6%) is likely to benefit from the recovery trade in the industry, argues Citi analyst Patrick Donnelly upgrading the stock to buy from neutral.The price target of $150.00 per share indicates a premium of ~22.4% to the previous close, and the stock is trading marginally higher today.Citing easier comps and potential recovery in the end market, the analyst views Agilent as attractive compared to other ‘Tools names’ such as Thermo Fisher Scientific ([[TMO]] +1.9%) and PerkinElmer ([[PKI]] +2.0%) which reaped outsized benefits from COVID testing.After stronger comps, Thermo Fisher Scientific and PerkinElmer have challenging times in FY21, the analyst argues expecting investors to focus on likely declines in revenue and margin.Despite an assumption of few more years of double-digit revenue growth, Seeking Alpha contributor, Stephen Simpson remains neutral on PerkinElmer citing a not-so-compelling fair value.

For further details see:

Agilent seen as a beneficiary in post-pandemic recovery trade at Citi